Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 14,783
  • Shares Outstanding, K 4,310
  • Annual Sales, $ 400 K
  • Annual Income, $ -16,950 K
  • 36-Month Beta 1.66
  • Price/Sales 36.30
  • Price/Cash Flow 0.00
  • Price/Book 0.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.27 +4.31%
on 08/11/17
4.58 -25.52%
on 07/18/17
-1.11 (-24.54%)
since 07/17/17
3-Month
3.27 +4.31%
on 08/11/17
5.25 -35.03%
on 05/31/17
-0.57 (-14.30%)
since 05/17/17
52-Week
3.27 +4.31%
on 08/11/17
21.30 -83.99%
on 12/15/16
-15.94 (-82.37%)
since 08/17/16

Most Recent Stories

More News
Financial Milestone Achieved in Catalyst's Subcutaneous Factor IX Program

Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a financial...

CBIO : 3.45 (+0.58%)
Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model

-- Data support ongoing clinical trial in individuals with hemophilia B --

CBIO : 3.45 (+0.58%)
Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, and ISU Abxis Co Ltd. (KOSDAQ: 086890) a commercial-stage...

CBIO : 3.45 (+0.58%)
Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting

-- Factor IX oral presentation & Factor VIIa poster presentation --

CBIO : 3.45 (+0.58%)
Today's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma

NEW YORK, NY / ACCESSWIRE / June 1, 2017 / U.S. markets dipped Wednesday, but still posted a monthly gain in May. The Dow Jones Industrial Average declined 0.10 percent to close at 21,008.65, up 0.46...

CBIO : 3.45 (+0.58%)
MEIP : 2.77 (+0.36%)
Bear of the Day: AMAG Pharmaceuticals (AMAG)

Bear of the Day: AMAG Pharmaceuticals (AMAG)

AKTX : 4.00 (-2.20%)
CBIO : 3.45 (+0.58%)
REGN : 468.04 (-0.11%)
AMAG : 17.67 (+1.26%)
Bear of the Day: AMAG Pharmaceuticals (AMAG)

Bear of the Day: AMAG Pharmaceuticals (AMAG)

AKTX : 4.00 (-2.20%)
CBIO : 3.45 (+0.58%)
REGN : 468.04 (-0.11%)
AMAG : 17.67 (+1.26%)
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update

-- Raised ~$20 million through an underwritten equity offering --

CBIO : 3.45 (+0.58%)
Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy

Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy

PTCT : 18.00 (+1.75%)
SLCA : 26.18 (+5.18%)
PTEN : 15.45 (-0.52%)
CBIO : 3.45 (+0.58%)
DXC : 85.23 (-0.65%)
5 Stocks with Earnings Acceleration to Buy Now

Earnings acceleration should be viewed as a key metric for share price outperformance

PTCT : 18.00 (+1.75%)
SLCA : 26.18 (+5.18%)
PTEN : 15.45 (-0.52%)
CBIO : 3.45 (+0.58%)
DXC : 85.23 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Support & Resistance

2nd Resistance Point 3.63
1st Resistance Point 3.53
Last Price 3.45
1st Support Level 3.31
2nd Support Level 3.19

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.